Clinical trials: Prostatic Hyperplasia
Benign Prostatic Hyperplasia
Study of Tadalafil Once-a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia
This is a randomized, double-blind, placebo-controlled, parallel-design, multinational, 12-week study to compare the efficacy, dose response, and safety of tadalafil once a day versus placebo in men with signs and symptoms of…
- Trial name
- NCT00384930
- Testing
- tadalafil
- Where
- United States
- Volunteers
- 1,058 people
- Sponsor
- Eli Lilly and Company
Benign Prostatic Hyperplasia
Effects of Tadalafil Once a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia
The purpose of this study is to evaluate the function of the bladder and urethra during urinary storage or voiding in men with signs and symptoms of benign prostatic hyperplasia treated with either placebo or tadalafil.
- Trial name
- NCT00386009
- Testing
- Tadalafil
- Where
- 13 sites in United States, Greece and 1 more
- Volunteers
- 200 people
- Sponsor
- Eli Lilly and Company
Benign Prostatic Hyperplasia
Effect of Dutasteride on Bladder Wall Hypertrophy in Patients With Benign Prostatic Obstruction
Increased bladder mass occurs as a consequence of bladder outlet obstruction in animals and patients, and relief of bladder outlet obstruction reverses an increased bladder mass.
- Trial name
- NCT00827814
- Testing
- Dutasteride
- Where
- South Korea
- Volunteers
- 36 people
- Sponsor
- Samsung Medical Center
Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia
Impact of 80 W KTP Laser Vaporization Prostatectomy on Severity of Obstruction in Benign Prostatic Hyperplasia
The purpose of this study is to compared the efficacy of 80W KTP photoselective laser vaporization prostatectomy (PVP) and transurethral resection of the prostate (TURP) in reducing the volume of prostate and relieving the…
- Trial name
- NCT00908427
- Testing
- photoselective vaporization prostatectomy (PVP), Transurethral resection of the prostate
- Where
- South Korea
- Volunteers
- 86 people
- Sponsor
- Samsung Medical Center
Benign Prostatic Hyperplasia
Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia
The purpose of this trial is to evaluate the dose response relationship of lonidamine and the primary efficacy endpoint, International Prostate Symptom Score (IPSS), in subjects with symptomatic benign prostatic hyperplasia (BPH).
- Trial name
- NCT00237536
- Testing
- Lonidamine
- Where
- 34 sites in United States
- Volunteers
- 240 people
- Sponsor
- Threshold Pharmaceuticals
Benign Prostatic Hyperplasia, Enlarged Prostate
Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia
The purpose of this study is to evaluate the efficacy of lonidamine (50mg, 150mg) compared to placebo in subjects with symptomatic BPH.
- Trial name
- NCT00435448
- Testing
- Lonidamine
- Where
- 58 sites in Germany, Hungary and 2 more
- Volunteers
- 480 people
- Sponsor
- Threshold Pharmaceuticals
Benign Prostate Hyperplasia
Effects of Isoflavone in Patients With Watchful Waiting Benign Prostate Hyperplasia
Benign prostatic hyperplasia (BPH) is a common problem among aging Caucasian men that produces significant morbidity and hea1th care costs. It is likely that BPH is just as common among Chinese men.
- Trial name
- NCT00861588
- Testing
- isoflavones (Soylife 25)
- Where
- Hong Kong
- Volunteers
- 176 people
- Sponsor
- Chinese University of Hong Kong
Prostatic Hyperplasia, Acute Urinary Retention
ALFAURUS : A DB Randomized Parallel Group Study of Alfuzosin 10mg OD vs Placebo in the Management of AUR in Patients With a 1st Episode Due to BPH
To assess the efficacy of alfuzosin 10mg OD in the management of acute urinary retention associated with BPH. To assess the safety of alfuzosin in this population and health care consumption.
- Trial name
- NCT00290030
- Testing
- Alfuzosin
- Volunteers
- 800 people
- Sponsor
- Sanofi
Benign Prostatic Hyperplasia
Evaluation of the Efficacy and Safety of Silodosin in the Treatment of the Signs and Symptoms of BPH
A new drug for the treatment of benign prostatic hyperplasia is compared with placebo and tamsulosin (a drug belonging to the same therapeutic class) for to determine if it is safe and effective (the first phase of the study…
- Trial name
- NCT00359905
- Testing
- Silodosin, Tamsulosin
- Where
- United Kingdom
- Volunteers
- 1,228 people
- Sponsor
- RECORDATI GROUP
Prostatic Hyperplasia, Urinary Bladder, Overactive
A Randomized, Double-Blinded, Placebo-Controlled, Two-Way Crossover Study to Investigate the Safety and Toleration of Single Dose Sildenafil in Subjects Receiving Chronic UK-369,0031
To investigate the safety and overall tolerability of co-administration two PDE5 inhibitors UK369,003 and sildenafil
- Conditions
- Prostatic Hyperplasia, Urinary Bladder, Overactive, Erectile Dysfunction
- Trial name
- NCT00814736
- Testing
- UK369,003, sildenafil
- Where
- Singapore
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Pfizer
Benign Prostatic Hyperplasia
Pharmacovigilance Study To Evaluate Safety Of AVODART In Subjects With Benign Prostate Hyperplasia
This study has 4 phases: screening phase (visit 1), treatment phase (visit 2 - 6 mths after treatment initiation), and end of treatment phase (visit 3 - end of year 1).
- Trial name
- NCT00593593
- Volunteers
- 1,000 people
- Sponsor
- GlaxoSmithKline
BPH, Benign Prostatic Hyperplasia
Bipolar vs Monopolar Transurethral Resection of the Prostate (TURP)
This study will prospectively evaluate a new electrosurgical procedure (bipolar transurethral prostatectomy) in men with symptomatic benign prostatic hyperplasia.
- Trial name
- NCT00199550
- Testing
- Bipolar Transurethral Resection of the Prostate, Monopolar Transurethral Resection of the Prostate
- Where
- 6 sites in Canada
- Volunteers
- 43 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Urinary Retention, Prostatic Hyperplasia
Clinical Trial in Males With BPH (Enlarged Prostate)
A study to determine the effect on prevention of Acute Urinary Retention (inability to urinate) in males with an enlarged prostate, also known as BPH. Free study-related medical care provided.
- Conditions
- Urinary Retention, Prostatic Hyperplasia, Benign Prostatic Hypertrophy
- Trial name
- NCT00029822
- Testing
- Alfuzosin (SL770499)
- Where
- 54 sites in United States, Australia and 15 more
- Volunteers
- 1,522 people
- Sponsor
- Sanofi
Benign Prostatic Hyperplasia
A Study to Determine the Improvement of the Symptoms of Benign Prostatic Hyperplasia (BPH) When Switching Subjects From Proscar to Avodart
Hypothesis: Dutasteride will perform better than finasteride in decreasing prostate volume, improving symptoms based on International Prostate Symptom score,and lower pvr based on the scientific information that dutasteride…
- Trial name
- NCT00690950
- Testing
- Dutasteride
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Urologic Consultants of Southeastern PA
Urinary Retention, Benign Prostatic Hyperplasia
Treatment of Refractory Urinary Retention Secondary to Benign Prostatic Hyperplasia (BPH) With Dual Five Alpha Reductase Inhibition Combined With an Alpha Blocker
To determine whether the addition of a dual Five Alpha Reductase Inhitor (Dutasteride) will alleviate urinary retention secondary to BPH in who have failed a voiding trial without a catheter.
- Trial name
- AUR (NCT00680680)
- Testing
- Dutasteride
- Volunteers
- 20 people
- Sponsor
- Franklin D. Gaylis, MD Inc.
Benign Prostatic Hyperplasia
Holmium Laser Ablation of the Prostate (HoLAP) Versus KTP Laser Vaporization of the Prostate
Many options currently exist to relieve the symptoms caused by benign prostatic hyperplasia (BPH). At present, transurethral resection of the prostate (TURP) serves as the surgical standard to which all other operative treatments…
- Trial name
- NCT00169767
- Testing
- Comparison study between KTP and HoLAP for BPH
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Indiana Kidney Stone Institute
Benign Prostatic Hyperplasia
Once Daily Given Alfuzosin in the Treatment of BPH
Collection of the data on the safety and efficacy of the once daily administration of the alfuzosin preparation /Alfetim Uno® l0 mg/ at patients with lower urinary tract symptoms/complaints rendering possible the presence of…
- Trial name
- NCT00637715
- Testing
- Alfuzosin
- Where
- Hungary
- Volunteers
- 60 people
- Sponsor
- Sanofi
Benign Prostatic Hyperplasia
A Prospective Evaluation of the GreenLight Model 120 Laser
The purpose of this study is to evaluate the performance of the GreenLight™ model 120 delivering higher average power to allow for more flexibility in the working distance of the delivery device with the same power density to…
- Trial name
- NCT00364585
- Testing
- GreenLight Model 120 Laser System
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Prostatic Hyperplasia
Male Sexual Health Questionnaire (MSHQ) - Sexual Function Study
Primary: To assess improvement in ejaculation from baseline to the end of treatment (Week 12 or premature withdrawal) with Alfuzosin 10mg OD, using MSHQ score.
- Trial name
- NCT00427882
- Testing
- ALFUZOSIN
- Where
- South Korea
- Volunteers
- 125 people
- Sponsor
- Handok Inc.
Benign Prostatic Hyperplasia
Effects Of Dutasteride On Risk Reduction Of Acute Urinary Retention Relapse Following Trial Without Catheter
The purpose of this study is to evaluate the efficacy and safety of dutasteride at reducing relapse rates of Acute Urinary Retention (AUR), including reduction in surgical intervention for benign prostatic hyperplasia (BPH), in…
- Trial name
- NCT00421421
- Testing
- Dutasteride
- Where
- 25 sites in United Kingdom
- Volunteers
- 276 people
- Sponsor
- GlaxoSmithKline